Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115 on ClinicalTrials.gov · last registry update 2016-12-16

An unusually large phase 2: 361 participants, more than double the 110 typical for the stage. The sponsor logged completion for May 2008. Primary outcome, as filed: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 361
Started: 2007-04
Primary completion: 2008-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.